$Adverum Biotechnologies(ADVM.US)$Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD 4 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE – Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints – – Preliminary safety data support a favorable benefit-risk pr...
$Adverum Biotechnologies(ADVM.US)$2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass. Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
$Adverum Biotechnologies(ADVM.US)$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025
$Adverum Biotechnologies(ADVM.US)$I’ll probably sell most position at $2. I feels like phase 2 is great, and they are working with some IB to do stock offering once news is out.
Adverum Biotechnologies股票討論區
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
reverse split焉有不跌的?
Update
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
Sold half at 1.8 but chart look good
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
$EyePoint Pharmaceuticals(EYPT.US)$
$Adverum Biotechnologies(ADVM.US)$
$Regenxbio(RGNX.US)$
$4D Molecular Therapeutics(FDMT.US)$
$Kodiak Sciences(KOD.US)$
feels like insider action.
暫無評論